No approved or evidence-based human dose has been established for men.
Research use only
Endocrine & body composition
CJC-1295 No DAC
A research analogue studied for its interaction with growth-hormone-releasing hormone pathways without a drug-affinity complex.
CJC-1295 No DAC5 mg
Add a Featured Image in WordPress to replace this product placeholder.
ClassificationShort-acting GHRH analogue
Catalogue strength5 mg
Current contextResearch use only
What it is
A research analogue studied for its interaction with growth-hormone-releasing hormone pathways without a drug-affinity complex.
Its catalogue classification is short-acting ghrh analogue. Status and formulation matter: a research-labelled vial is not automatically equivalent to an authorized prescription medicine containing a similarly named ingredient.
What it is studied or used for
- GHRH receptor signalling
- Pulsatile growth-hormone models
- Endocrine pharmacology
A research topic is not proof of a health benefit. Evidence can range from cell and animal models to controlled human trials, and those levels should not be treated as equivalent.
How it is used or administered
This catalogue item is supplied for laboratory research. It is not accompanied by directions for self-administration or therapeutic use.
Dosing context for men and women
No approved or evidence-based human dose has been established for women.
Why no universal number? Dose depends on the exact formulation, legal status, indication, concentration, patient factors and monitoring. Publishing a single male or female number would be misleading and unsafe.
Active shelf life and storage
Use only within the lot-specific expiry shown on the vial, packaging or certificate of analysis. A universal peptide shelf life cannot be inferred from appearance alone.
Keep lyophilized material refrigerated and protected from light as stated on the product label. Reconstituted stability is compound-, diluent- and protocol-specific; follow a validated laboratory protocol.
What it may be paired with
It is often discussed alongside ghrelin-receptor agonists such as ipamorelin, but no approved human combination or home-use protocol exists.
Safety boundary
Not intended for human or veterinary consumption, diagnosis, treatment or disease prevention.
Continue with primary sources
Evidence and regulatory status change. Verify the exact active ingredient, formulation and jurisdiction before drawing conclusions.
Product availability
View CJC-1295 No DAC on the main site ↗
Ready to leave the education library?
Purchasing, pricing, shipping and product-specific lot information are handled on the main Cryos Bio Labs website.